Advertisement

Topics

Novartis gets first-line approval for Xalkori challenger in EU

07:42 EDT 29 Jun 2017 | PMLIVE

Zykadia showed a 45% reduction in the risk of disease progression compared to chemo

Original Article: Novartis gets first-line approval for Xalkori challenger in EU

NEXT ARTICLE

More From BioPortfolio on "Novartis gets first-line approval for Xalkori challenger in EU"

Quick Search
Advertisement